NCT04657861 is a EARLY_PHASE1 clinical trial of APRIL CAR-T cells in Multiple Myeloma in Relapse, sponsored by Zhejiang University.

Who is sponsoring NCT04657861?

NCT04657861 is sponsored by Zhejiang University.

What drugs are being tested in NCT04657861?

Interventions in NCT04657861: APRIL CAR-T cells.

What condition does NCT04657861 study?

NCT04657861 studies Multiple Myeloma in Relapse, Multiple Myeloma, Refractory.

Is NCT04657861 still recruiting?

NCT04657861 is currently recruiting now. Last updated 9 May 2022.

Last reviewed 2022-05-09 · How we verify

NCT04657861

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma

Recruiting now EARLY_PHASE1 Last updated 9 May 2022

What this trial tests

EARLY_PHASE1 trial testing APRIL CAR-T cells in Multiple Myeloma in Relapse in 36 participants. Currently enrolling.

Timeline

3 May 2022

Primary endpoint
20 August 2024

20 August 2027

Quick facts

Lead sponsor	Zhejiang University
Phase	EARLY_PHASE1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	36
Start date	3 May 2022
Primary completion	20 August 2024
Estimated completion	20 August 2027
Sites	1 location across China

Drugs / interventions tested

APRIL CAR-T cells — full drug profile →

Conditions studied

Multiple Myeloma in Relapse — all drugs for Multiple Myeloma in Relapse →
Multiple Myeloma, Refractory — all drugs for Multiple Myeloma, Refractory →

Sponsor

Zhejiang University

Who can join

Adults 18 to 75, any sex, with Multiple Myeloma in Relapse or Multiple Myeloma, Refractory. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A study of APRIL CAR-T cells therapy for patients with BCMA/TACI positive relapsed and/or refractory multiple myeloma

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

CAR T therapies in multiple myeloma: unleashing the future.
Sheykhhasan M, Sheykhhasan M, Ahmadieh-Yazdi A, Vicidomini R, et al · · 2024 · cited 109× · PMID 38438559 · DOI 10.1038/s41417-024-00750-2
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
Kegyes D, Constantinescu C, Vrancken L, Rasche L, et al · · 2022 · cited 53× · PMID 35672793 · DOI 10.1186/s13045-022-01296-2
Next-generation chimeric antigen receptors for T- and natural killer-cell therapies against cancer.
Li Y, Rezvani K, Rafei H. · · 2023 · cited 29× · PMID 37548050 · DOI 10.1111/imr.13255
Natural Receptor- and Ligand-Based Chimeric Antigen Receptors: Strategies Using Natural Ligands and Receptors for Targeted Cell Killing.
Branella GM, Spencer HT. · · 2021 · cited 23× · PMID 35011583 · DOI 10.3390/cells11010021
Past, Present, and a Glance into the Future of Multiple Myeloma Treatment.
Elbezanti WO, Challagundla KB, Jonnalagadda SC, Budak-Alpdogan T, et al · · 2023 · cited 20× · PMID 36986514 · DOI 10.3390/ph16030415
Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment.
Ho M, Xiao A, Yi D, Zanwar S, et al · · 2022 · cited 20× · PMID 36421358 · DOI 10.3390/curroncol29110705
CRISPR, CAR-T, and NK: Current applications and future perspectives.
Khoshandam M, Soltaninejad H, Hamidieh AA, Hosseinkhani S. · · 2024 · cited 11× · PMID 38545126 · DOI 10.1016/j.gendis.2023.101121
Updates on CAR T cell therapy in multiple myeloma.
Nasiri F, Asaadi Y, Mirzadeh F, Abdolahi S, et al · · 2024 · cited 10× · PMID 39261906 · DOI 10.1186/s40364-024-00634-5

Verify or expand the search:

Other recruiting trials for Multiple Myeloma in Relapse

Currently open trials in the same condition.

NCT07096778 — Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
NCT06822972 — HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM · Phase 2 · recruiting
NCT07032129 — Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma · Phase 1, PHASE2 · recruiting
NCT07248176 — Universal CAR-T Cell Therapy for MM · NA · recruiting
NCT06846905 — Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma. · recruiting

Other Zhejiang University trials

Trials by the same sponsor.

NCT07487402 — Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurr · EARLY_PHASE1 · not yet recruiting
NCT07480044 — A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly · NA · not yet recruiting
NCT07467005 — Video Double-Lumen Tube for Secondary Pulmonary Resection · NA · not yet recruiting
NCT07429461 — Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
NCT07240766 — HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04657861 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhejiang University
Last refreshed: 9 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04657861.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing